

# Stephan Miehle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6844098/publications.pdf>

Version: 2024-02-01

37  
papers

3,545  
citations

304743

22  
h-index

345221

36  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2249  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Process of Developing a Disease Activity Index in Microscopic Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 452-459.	1.3	5
2	Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme. <i>United European Gastroenterology Journal</i> , 2022, 10, 330-343.	3.8	11
3	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. <i>United European Gastroenterology Journal</i> , 2021, 9, 13-37.	3.8	122
4	Distribution of histopathological features along the colon in microscopic colitis. <i>International Journal of Colorectal Disease</i> , 2021, 36, 151-159.	2.2	18
5	Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1174-1183.	1.3	22
6	Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial. <i>United European Gastroenterology Journal</i> , 2021, 9, 837-847.	3.8	7
7	Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092728.	3.2	24
8	Therapie mikroskopischer Kolididen und eosinophiler Erkrankungen des Gastrointestinaltraktes. , 2020, , 367-371.		0
9	Clinical management of eosinophilic esophagitis – a nationwide survey among gastroenterologists in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 745-752.	0.5	21
10	Mo1129 – Efficacy of Budesonide Orodispersible Tablets for Induction of Remission in Patients with Active Eosinophilic Esophagitis: Results from the 6-Weeks Open-Label Treatment Phase of Eos-2 Trial. <i>Gastroenterology</i> , 2019, 156, S-715.	1.3	5
11	Mo1130 – Budesonide Orodispersible Tablets Can Effectively Induce Complete Remission of Endoscopic and Histologic Mucosal Abnormalities and Can Induce Deep Disease Remission in Active Eosinophilic Esophagitis: Results from a Post-Hoc Analysis of the Randomized, Double-Blind, Placebo-Controlled Eos-1 Trial. <i>Gastroenterology</i> , 2019, 156, S-715-S-716.	1.3	5
12	Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 74-86.e15.	1.3	170
13	Microscopic colitis: pathophysiology and clinical management. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 305-314.	8.1	87
14	8. Mikroskopische Koliditis. , 2019, , 103-116.		0
15	Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1574-1581.	2.8	30
16	Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. <i>Gastroenterology</i> , 2018, 155, 1795-1804.e3.	1.3	52
17	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	1.3	712
18	Sa1145 - Predictors for Early Versus Delayed Response to Budesonide Orodispersible Tablets in Eosinophilic Esophagitis Treatment: A Subgroup Analysis from the Pivotal Trial Eos-1. <i>Gastroenterology</i> , 2018, 154, S-256-S-257.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. <i>Gut</i> , 2017, 66, 421-428.	12.1	50
20	Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. <i>United European Gastroenterology Journal</i> , 2017, 5, 335-358.	3.8	718
21	Efficacy of three- vs one capsule bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication in clinical practice in a multinational patient population. <i>Helicobacter</i> , 2017, 22, e12429.	3.5	12
22	Smoking Status Influences Clinical Outcome in Collagenous Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 449-454.	1.3	24
23	Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. <i>Gut</i> , 2016, 65, 47-56.	12.1	69
24	A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. <i>Gut</i> , 2016, 65, 390-399.	12.1	165
25	Clinical features of Eosinophilic esophagitis in children and adults. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 739-748.	2.4	41
26	Histology of microscopic colitis—review with a practical approach for pathologists. <i>Histopathology</i> , 2015, 66, 613-626.	2.9	155
27	Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis. <i>Gastroenterology</i> , 2014, 146, 1222-1230.e2.	1.3	106
28	Induction of Eosinophilic Esophagitis by Sublingual Pollen Immunotherapy. <i>Case Reports in Gastroenterology</i> , 2013, 7, 363-368.	0.6	112
29	Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2011, 16, 420-426.	3.5	49
30	Probe-based Confocal Laser Endomicroscopy in Double Balloon Enteroscopy. <i>Zeitschrift Fur Gastroenterologie</i> , 2011, 49, 1529-1534.	0.5	4
31	Should quinolones come first in <i>Helicobacter pylori</i> therapy?. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 103-114.	3.2	51
32	Budesonide Is Effective in Treating Lymphocytic Colitis: A Randomized Double-Blind Placebo-Controlled Study. <i>Gastroenterology</i> , 2009, 136, 2092-2100.	1.3	158
33	One-Week Once-Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent <i>Helicobacter pylori</i> Resistant to Both Metronidazole and Clarithromycin. <i>Helicobacter</i> , 2008, 13, 69-74.	3.5	62
34	Oral Budesonide for Maintenance Treatment of Collagenous Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2008, 135, 1510-1516.	1.3	119
35	Effective regimens for the treatment of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 995-1016.	4.1	21
36	Oral budesonide therapy improves quality of life in patients with collagenous colitis. <i>International Journal of Colorectal Disease</i> , 2005, 20, 312-316.	2.2	76

#	ARTICLE	IF	CITATIONS
37	Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial. <i>Gastroenterology</i> , 2002, 123, 978-984.	1.3	254